Companies/SG/K6S

PRUDENTIAL PLC

Last · SES$14.20+0.0000001907 (+0.00%)stale · yahoo · 1821h ago
Market cap$35.20B2.48B sh
P/E · TTM10.0fwd 14.2 · eps 1.42
Beta0.90vs S&P 500
Div yield1.94%annual · TTM
52w range
$9.04$15.80
Volume100session

Issuer

Legal namePRUDENTIAL PLC
HQSingapore (SG)
ListingSG K6S
CurrencySGD
Entity registrysgx:K6S
Loading chart…

OpenFilings analyst

Our analyst

Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.

Strong capital returns and execution are offset by China, regulatory, and agency-delivery risks that keep this from being a clean buy.

Latest call · 2026-08-27

Hold: Prudential delivered a strong first half—EPS rose 17%, gross OFSG 15%, net OFSG 41%, new business profit 8%, and the new business margin expanded 2 percentage points to 40%—while adding a further $0.3 billion to the 2026 buyback. However, the full-year double-digit-growth outlook still depends on a demanding second half, China recovery, Hong Kong momentum, and agency transformation; China’s margin is expected to fall to about 40% from 45% in 2025, and active agents declined to 55,000.

Themes
  • 2026 Guidance
  • Hong Kong Mainland Visitors
  • Mainland China Margin
  • Agency Transformation
  • Capital Returns
  • India Life Health
+1

Near term

Execution against unchanged 2026 double-digit-growth guidance, particularly the high-comparator July-August period in Hong Kong and mainland China.

Mainland China recovery from September, with management targeting a normalized par mix of about 60% versus 76% in H1 and a full-year margin of roughly 40%.

Hong Kong Chinese-mainland-visitor demand and domestic growth; management expects full-year Hong Kong new business profit growth to be double-digit.

Completion of the additional $0.3 billion 2026 buyback and progress toward returning residual proceeds from the India asset-management and insurance transactions.

Singapore margin recovery after co-payment-related health regulation changes and the pace of improvement in agency productivity.

Longer term

Conversion of new business profit into cash and delivery of the $4.4 billion 2027 OFSG target are central to the investment case.

Agency transformation is shifting from mass recruitment toward higher-quality full-time recruits; the thesis improves materially if active agents resume growth without sacrificing productivity.

Completion of the $300-$350 million 2026 capability investment programme and sustainable positive operating variances could lift ROEV from 15% by 2-3 percentage points.

India could become a material franchise over 5-10 years through controlled life and health platforms, but the opportunity remains dependent on regulatory approval and execution across a limited city footprint.

Competitive and structural moat risk remains tied to whether Prudential can sustain premium advice, agency productivity, and bancassurance distribution while Chinese regulation and product-mix changes pressure margins.

Red flags

Management maintained guidance but acknowledged high comparators, China regulatory disruption, bancassurance expense-rule changes, and a difficult second half; delivery therefore remains execution-sensitive.

China par products reached 76% of first-half mix, compressing margins, and management only expects normalization to about 60% for the full year rather than an immediate return to prior mix.

Total active agents fell to 55,000. Management emphasized quality and productivity, but did not provide a clear timetable or target for returning the base to growth.

Hong Kong exposure remains meaningful: approximately half of Hong Kong value of in-force relates to mainland visitors, creating sensitivity to tax-enforcement headlines and cross-border demand despite currently strong persistency.

India’s strategic upside is largely aspirational at this stage, with the life transaction subject to regulatory approval and no quantified earnings or capital-return contribution provided.

Recommendation history

OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.

Upcoming earnings

1 event
No actuals reported
Period
Jun 2026
Est. EPS
Est. revenue
0

Earnings transcripts

12 of 29 recent

Documents